THE SHORT ANSWER
What does the maintenance trial tell us?
Among participants randomized after a 36-week tirzepatide lead-in, continuing treatment maintained and extended weight reduction; switching to placebo led to regain.
The important limitation
670 participants were randomized after the lead-in. This is not the same population as all 783 who entered it.
Illustrative correction: the trial populations are distinguished in this sample. View the example change
ONE STEP DEEPER
Open the evidence.
See how the study was designed and where its findings apply.
KEEP THE SCOPE IN VIEW
Safety & regulatory context.
SURMOUNT-1 reported gastrointestinal adverse events, mainly during dose escalation. A weight-loss outcome alone does not establish personal suitability.
No approval status is inferred from a compound name. Jurisdiction, formulation, indication, and a dated primary source are needed for a regulatory entry.
How to read safety & statusCHECK THE ORIGINAL RESEARCH
Sources you can inspect.
- 01
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Aronne LJ et al. · JAMA · 2024
- 02
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM et al. · New England Journal of Medicine · 2022
A VISIBLE RECORD
What changed here?
Separate the lead-in from the randomized population.
An illustrative correction keeps the denominator attached to the trial phase.
Open the change record